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1. Preparing the dataset For each person the time of follow-up, the
event status at end of follow-up (e.g., dead:
yes/no), the exposure (e.g., presence of
CKD: yes/no), and any variables to control
for (e.g., age at time of cardiac surgery in
years) must be available.
2. Descriptive analyses: calculation The Kaplan–Meier method estimates
absolute cumulative risk while taking into
account censoring. It will provide
cumulative survival probabilities, which
can be plotted for descriptive purposes.
3. Descriptive analyses: reporting – Median follow-up time.
– Numbers of events or summary mea-sures over time, e.g., the number of
deaths or the number of deaths per 100
person years.– The Kaplan–Meier survival plot, with
preferably the numbers of participants
still at risk at different follow-up times
under the time axis.
– A summary of the survival (e.g., one--
year all- cause mortality and median
survival time).
4. Effect size estimation: calculation The Cox regression analysis is the most
popular method to provide an effect estimate
(hazard ratio) with an accompanying
conﬁdence interval. It quantiﬁes the relative
difference in survival between patient groups.
Using Cox regression analyses one can also
adjust for confounding effects of other
variables in order to make more fair survival
comparisons.
5. Effect size estimation: reporting – Both the unadjusted and adjusted haz-
ard ratios with their accompanying
conﬁdence intervals.
– Make clear which variables were con-
trolled for and why.
– The survival plot adjusted for potential
confounders (optional).
6. Proportional hazard assumption
for Cox regression analysis:
checking
For each independent variable, the
proportional hazard assumption should be
checked graphically or by formal tests of
signiﬁcance.
7. Proportional hazard assumption
for Cox regression analysis:
– Report whether or not the proportional
hazard assumption holds.Many studies in cardiology research investigate the time to an event
(e.g., all cause death) as their primary outcome variable. Usually, exact
times to such an event are only known for some but not for all patients,
as not all patients may have experienced the event of interest at the
time of statistical analysis. Therefore, special methods accounting for
such incomplete ‘censored’ observations were developed to analyse
time-to-event data [1]. The Kaplan–Meier (KM) method is the method
of choice to estimate cumulative survival probabilities of patient groups
in the presence of censoring. Cox proportional hazards regression pro-
vides estimates of effect size and extends simple group comparisons by
accounting for confounding factors. In this letter we elaborate on the
seven essential tools for performing survival analyses and for reporting
of their results.
To explain these seven tools, we make use of a hypothetical clinical
example. Assume that the aim of a studywas to examine the association
between the presence of pre-operative chronic kidney disease (CKD)
and one-year all-causemortality in patients undergoing cardiac surgery.
In this study we included 50 patients with pre-operative CKD (deﬁned
as an estimated glomerular ﬁltration rate ≤60 ml/min/1.73 m2) and
500 patients without pre-operative CKD who all went for cardiac
surgery between 1 January 2010 and 31 December 2013. The patients'
observation period started at the day of cardiac surgery. The end ofic Medical Center, Department
msterdam, The Netherlands.
reporting – If not, one may need to report hazard
ratio estimates for various periods dur-
ing follow-up rather than a single con-
stant hazard ratio.
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Fig. 1. Survival plots estimated by the KMmethod: (a) cumulative survival (y axis 0–1.0), (b) cumulative mortality (y axis 0–0.8); and by Cox regression analysis (c) cumulative survival
adjusted for age at time of cardiac surgery. The numbers below the ﬁgures denote the number of patients ‘at risk’ in each group. Using the KM method, the log-rank test provided a
p-value b 0.001. Using Cox regression analysis, the unadjusted hazard ratio (HR) with 95% conﬁdence interval for the patients with CKD compared to the patients without CKD was
3.30 (95% CI: 2.11–5.14). The HR adjusted for age at day of cardiac surgery (HRadj) was 2.80 (95% CI: 1.77–4.41).
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was death.
Table 1 provides an overview of the seven essential tools for survival
analyses. The ﬁrst tool is preparing the dataset as required to perform
KM or Cox regression analyses in statistical packages like SPSS, STATA
or SAS. The database of our clinical example includes a patient identiﬁer,
time of follow-up (days), status at end of follow-up (0 = alive, 1 =
death), CKD (0 = no, 1 = yes), and age at time of cardiac surgery
(years).
The second tool is performing descriptive analyses. The KMmethod
will calculate cumulative survival probabilities (the proportion of all
persons that were still alive at a given day) and cumulative mortality
probabilities (1 minus the cumulative survival probability) [2]. Statisti-
cal packages can easily calculate this.
The third tool is the reporting of the descriptive analyses. As rec-
ommended by the STROBE and CONSORT statements, cohort studies
and randomized controlled trials should summarize the follow-up
time and report numbers of events or summary measures of these
events over time [3,4]. Additionally, an unadjusted survival curve es-
timated by the KM method should be part of the initial data analysisreport (see Fig. 1a, b) [5]. Also, survival may be summarized by pro-
viding the survival probability after a speciﬁc follow-up time or the
median survival time (i.e., time when the cumulative survival prob-
ability drops below 50%). In our clinical example, the one-year cu-
mulative survival probability was 43% in CKD patients and 79% in
non-CKD patients. Median survival in the CKD group was 325 days
from cardiac surgery (Fig. 1a). In the non-CKD group, however, the
cumulative survival did not drop below 50% within one year, and
the precise median survival time can only be reported using longer
follow-up time. Furthermore, when using the KM method, the log-rank
test provided a p-value b0.001 indicating that the survival difference be-
tween the CKD and non-CKD groups was statistically signiﬁcant and not
due to chance. However, the p-value does not provide any information
on the size of the survival difference neither does it yield a related conﬁ-
dence interval.
The fourth tool is the estimation of the effect size. Cox regression
analyses can calculate the size of the effect by providing a relative
risk of an exposure (in this case CKD) and allows multivariable anal-
ysis to adjust for confounders [6]. In most statistical packages the
output of Cox regression analysis provides an estimate of the
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companying 95% conﬁdence interval (95% CI) which expresses the
uncertainty about the estimated HR in the related population [7].
The ﬁfth tool is the reporting of the effect size. The unadjusted HR
of the patients with CKD compared to the patients without CKD was
3.30 (95% CI: 2.11–5.14), meaning that CKD patients had a 3.3 times
higher mortality risk than non-CKD patients. However, among
others, the variable ‘age at the time of cardiac surgery’ may be a con-
founder in the association between the presence of CKD and mortal-
ity after cardiac surgery, because patients with CKD were older than
those without CKD and for that reason may have a higher mortality
[8]. After adjustment for age, the HR of CKD decreased to 2.80 (95%
CI: 1.77–4.41). The presentation of results needs to include both
unadjusted and adjusted HRs with their 95% CIs. By comparing the
unadjusted and adjusted HR, it is possible to quantify to what
extent age confounded the association between the presence of
CKD at the time of cardiac surgery and mortality. Additionally,
one could use Cox regression analyses to compute survival curves
for CKD and non-CKD patients, given that all patients had the
same age at their cardiac surgery, thus providing an age-adjusted
comparison (Fig. 1c).
The sixth tool includes checking the ‘proportional hazard’ (PH)
assumption. The Cox regression model relies on this assumption, as-
suming that HRs are constant throughout the follow-up period.
Often, one may detect non-PH already by graphic inspection of the
unadjusted group-speciﬁc survival curves. The PH assumption
holds if curves have similar shapes, and if their separation remains
proportional over time. The PH assumption can also be tested for-
mally [9].
The seventh tool is reporting whether or not the PH assumption
holds. In case of non-PH, statistical software can be used to compute
follow-up time speciﬁc HRs to be included in analysis reports.
Our clinical example focused on all-cause death. However, sur-
vival analysis may also study cause-speciﬁc mortality like death
from cardiac causes. In that case, death from non-cardiac causes
‘competes’ with death from cardiac causes and methods appropriate
for the presence of ‘competing risks’ should be used [10].Conﬂict of interest
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